Kocher Thomas, Wagner Roland N, Klausegger Alfred, Guttmann-Gruber Christina, Hainzl Stefan, Bauer Johann W, Reichelt Julia, Koller Ulrich
EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Mol Ther Nucleic Acids. 2019 Dec 6;18:496-507. doi: 10.1016/j.omtn.2019.09.011. Epub 2019 Sep 20.
Current gene-editing approaches for treatment of recessive dystrophic epidermolysis bullosa (RDEB), an inherited, severe form of blistering skin disease, suffer from low efficiencies and safety concerns that complicate implementation in clinical settings. We present a strategy for efficient and precise repair of RDEB-associated mutations in the COL7A1 gene. We compared the efficacy of double-strand breaks (induced by CRISPR/Cas9), single nicks, or double nicks (induced by Cas9n) in mediating repair of a COL7A1 splice-site mutation in exon 3 by homologous recombination (HR). We accomplished remarkably high HR frequencies of 89% with double nicking while at the same time keeping unwanted repair outcomes, such as non-homologous end joining (NHEJ), at a minimum (11%). We also investigated the effects of subtle differences in repair template design on HR rates and found that strategic template-nicking can enhance COL7A1-editing efficiency. In RDEB patient keratinocytes, application of double-nicking led to restoration and subsequent secretion of type VII collagen at high efficiency. Comprehensive analysis of 25 putative off-target sites revealed no off-target activity for double-nicking, while usage of Cas9 resulted in 54% modified alleles at one site. Taken together, our work provides a framework for efficient, precise, and safe repair of COL7A1, which lies at the heart of a future curative therapy of RDEB.
目前用于治疗隐性营养不良性大疱性表皮松解症(RDEB,一种遗传性严重水疱性皮肤病)的基因编辑方法,存在效率低下和安全性问题,这使得其在临床环境中的应用变得复杂。我们提出了一种有效且精确修复COL7A1基因中与RDEB相关突变的策略。我们比较了双链断裂(由CRISPR/Cas9诱导)、单切口或双切口(由Cas9n诱导)通过同源重组(HR)介导外显子3中COL7A1剪接位点突变修复的效果。我们通过双切口实现了高达89%的显著高HR频率,同时将非同源末端连接(NHEJ)等不必要的修复结果保持在最低水平(11%)。我们还研究了修复模板设计中的细微差异对HR率的影响,发现策略性模板切口可提高COL7A1编辑效率。在RDEB患者角质形成细胞中,双切口的应用导致VII型胶原蛋白高效恢复并随后分泌。对25个假定脱靶位点的综合分析显示双切口无脱靶活性,而使用Cas9导致一个位点有54%的修饰等位基因。综上所述,我们的工作为COL7A1的高效、精确和安全修复提供了一个框架,这是未来RDEB治愈性疗法的核心。